1. Home
  2. IMNM vs PAHC Comparison

IMNM vs PAHC Comparison

Compare IMNM & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNM
  • PAHC
  • Stock Information
  • Founded
  • IMNM 2006
  • PAHC 1946
  • Country
  • IMNM United States
  • PAHC United States
  • Employees
  • IMNM N/A
  • PAHC N/A
  • Industry
  • IMNM Medicinal Chemicals and Botanical Products
  • PAHC Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMNM Health Care
  • PAHC Health Care
  • Exchange
  • IMNM Nasdaq
  • PAHC Nasdaq
  • Market Cap
  • IMNM 747.7M
  • PAHC 682.5M
  • IPO Year
  • IMNM 2020
  • PAHC 2014
  • Fundamental
  • Price
  • IMNM $12.01
  • PAHC $21.89
  • Analyst Decision
  • IMNM Strong Buy
  • PAHC Sell
  • Analyst Count
  • IMNM 5
  • PAHC 4
  • Target Price
  • IMNM $28.60
  • PAHC $20.50
  • AVG Volume (30 Days)
  • IMNM 803.1K
  • PAHC 145.8K
  • Earning Date
  • IMNM 11-13-2024
  • PAHC 02-05-2025
  • Dividend Yield
  • IMNM N/A
  • PAHC 2.15%
  • EPS Growth
  • IMNM N/A
  • PAHC N/A
  • EPS
  • IMNM N/A
  • PAHC 0.43
  • Revenue
  • IMNM $10,129,000.00
  • PAHC $1,046,762,000.00
  • Revenue This Year
  • IMNM N/A
  • PAHC $27.25
  • Revenue Next Year
  • IMNM N/A
  • PAHC $14.13
  • P/E Ratio
  • IMNM N/A
  • PAHC $51.99
  • Revenue Growth
  • IMNM N/A
  • PAHC 7.17
  • 52 Week Low
  • IMNM $7.76
  • PAHC $10.04
  • 52 Week High
  • IMNM $30.96
  • PAHC $25.98
  • Technical
  • Relative Strength Index (RSI)
  • IMNM 43.70
  • PAHC 39.62
  • Support Level
  • IMNM $12.99
  • PAHC $22.02
  • Resistance Level
  • IMNM $15.13
  • PAHC $24.42
  • Average True Range (ATR)
  • IMNM 0.93
  • PAHC 0.72
  • MACD
  • IMNM -0.16
  • PAHC -0.15
  • Stochastic Oscillator
  • IMNM 3.79
  • PAHC 12.92

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Share on Social Networks: